globalchange  > 气候变化事实与影响
DOI: 10.1289/ehp.1409396
论文题名:
Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial
作者: Br; ilyn A. Peters; 1* Megan N. Hall; 2* Xinhua Liu; 3 Faruque Parvez; 1 Tiffany R. Sanchez; 1 Alex; er van Geen; 4 Jacob L. Mey; 4 Abu B. Siddique; 5 Hasan Shahriar; 5 Mohammad Nasir Uddin; 5 Tariqul Islam; 5 Olgica Balac; 1 Vesna Ilievski; 1 Pam Factor-Litvak; 2 Joseph H. Graziano; 1; Mary V. Gamble1
刊名: Environmental Health Perspectives
ISSN: 0091-7339
出版年: 2015
卷: Volume 123, 期:Issue 12
起始页码: 1294
语种: 英语
英文摘要: Background: The World Health Organization estimates that > 140 million people worldwide are exposed to arsenic (As)–contaminated drinking water. As undergoes biologic methylation, which facilitates renal As elimination. In folate-deficient individuals, this process is augmented by folic acid (FA) supplementation, thereby lowering blood As (bAs). Creatinine concentrations in urine are a robust predictor of As methylation patterns. Although the reasons for this are unclear, creatine synthesis is a major consumer of methyl donors, and this synthesis is down-regulated by dietary/supplemental creatine.

Objectives: Our aim was to determine whether 400 or 800 μg FA and/or creatine supplementation lowers bAs in an As-exposed Bangladeshi population.

Methods: We conducted a clinical trial in which 622 participants were randomized to receive 400 μg FA, 800 μg FA, 3 g creatine, 3 g creatine+400 μg FA, or placebo daily. All participants received an As-removal filter on enrollment, and were followed for 24 weeks. After the 12th week, half of the two FA groups were switched to placebo to evaluate post-treatment bAs patterns.

Results: Linear models with repeated measures indicated that the decline in ln(bAs) from baseline in the 800-μg FA group exceeded that of the placebo group (weeks 1–12: β= –0.09, 95% CI: –0.18, –0.01; weeks 13–24: FA continued: β= –0.12, 95% CI: –0.24, –0.00; FA switched to placebo: β= –0.14, 95% CI: –0.26, –0.02). There was no rebound in bAs related to cessation of FA supplementation. Declines in bAs observed in the remaining treatment arms were not significantly different from those of the placebo group.

Conclusions: In this mixed folate-deficient/replete study population, 12- and 24-week treatment with 800 μg (but not 400 μg) FA lowered bAs to a greater extent than placebo; this was sustained 12 weeks after FA cessation. In future studies, we will evaluate whether FA and/or creatine altered As methylation profiles.
URL: https://ehp.niehs.nih.gov/1409396
Citation statistics:
被引频次[WOS]:68   [查看WOS记录]     [查看WOS中相关记录]
资源类型: 期刊论文
标识符: http://119.78.100.158/handle/2HF3EXSE/12668
Appears in Collections:气候变化事实与影响
气候变化与战略

Files in This Item: Download All
File Name/ File Size Content Type Version Access License
ehp.1409396.alt.pdf(403KB)期刊论文作者接受稿开放获取View Download

作者单位: 1Department of Environmental Health Sciences, 2Department of Epidemiology, and 3Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York, USA; 4Lamont-Doherty Earth Observatory, Columbia University, Palisades, New York, USA; 5Columbia University Arsenic Project in Bangladesh, Dhaka, Bangladesh

Recommended Citation:
Br,ilyn A. Peters,1* Megan N. Hall,et al. Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial[J]. Environmental Health Perspectives,2015-01-01,Volume 123(Issue 12):1294
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Br]'s Articles
[ilyn A. Peters]'s Articles
[1* Megan N. Hall]'s Articles
百度学术
Similar articles in Baidu Scholar
[Br]'s Articles
[ilyn A. Peters]'s Articles
[1* Megan N. Hall]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Br]‘s Articles
[ilyn A. Peters]‘s Articles
[1* Megan N. Hall]‘s Articles
Related Copyright Policies
Null
收藏/分享
文件名: ehp.1409396.alt.pdf
格式: Adobe PDF
此文件暂不支持浏览
所有评论 (0)
暂无评论
 

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.